FDA approves Safyral
WAYNE, N.J. — The Food and Drug Administration has approved a new oral contraceptive developed by Bayer.
Safyral is a combination of Yasmin, also developed by Bayer, with 451 mcg levomefolate calcium, which is a B vitamin known as a folate. It is the second oral contraceptive from Bayer that features folate.
"With the FDA approval of Safyral, Bayer now offers two oral contraceptives that contain folate," said Leslie North, VP women's healthcare marketing at Bayer HealthCare Pharmaceuticals. "Safyral and Beyaz are part of Bayer's growing women's health franchise, and these new products reinforce our commitment to providing women various contraceptive options."